A 57-year-old man with type 2 diabetes started a weekly injection to get his blood sugar under control. About two weeks later, his family and his coworkers told him he smelled bad.
Nothing about his life had changed. Not his diet, not his hygiene habits, not any of his other prescriptions. The only new variable was dulaglutide, the once-weekly GLP-1 receptor agonist sold in the United States as Trulicity. His doctors ran the odor down to the drug, then confirmed it the hard way: they stopped the medication, watched the smell disappear, gave the drug again, and watched it come back.
